ALNYLAM HIGHLIGHTS NEW DATA FROM HELIOS-B STUDY OF VUTRISIRAN FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY AT HEART FAILURE SOCIETY OF AMERICA ANNUAL SCIENTIFIC MEETING 2024

Reuters · 5d ago
ALNYLAM HIGHLIGHTS NEW DATA FROM HELIOS-B STUDY OF VUTRISIRAN FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY AT HEART FAILURE SOCIETY OF AMERICA ANNUAL SCIENTIFIC MEETING 2024